Fanelli Giuseppe Nicolò, Nuzzo Pier Vitale, Pederzoli Filippo, Loda Massimo
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 57, Pisa 56125, Italy.
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.
Surg Pathol Clin. 2025 Mar;18(1):25-39. doi: 10.1016/j.path.2024.10.003. Epub 2024 Nov 29.
Despite improvements in diagnosis and treatment approaches, prostate cancer (PC) remains a leading cause of cancer-related death in men. PC progresses through various stages, mostly driven by androgen receptor signaling. However, after androgen deprivation therapies, in a significant portion of patients, several different molecular mechanisms contribute to the development of castration resistance. Delving deeply into the molecular landscape of castration-resistant PC, grasping the selective pressures exerted by therapies, and understanding the drivers of lineage plasticity is pivotal to prevent progression. Targeting genetic and epigenetic alterations that drive this transition will guide clinical management strategies and possibly prevent and/or treat lethal disease.
尽管在诊断和治疗方法上有所改进，但前列腺癌（PC）仍是男性癌症相关死亡的主要原因。PC会经历各个阶段的发展，主要由雄激素受体信号传导驱动。然而，在雄激素剥夺治疗后，相当一部分患者会通过几种不同的分子机制产生去势抵抗。深入研究去势抵抗性PC的分子格局，掌握治疗所施加的选择性压力，并理解谱系可塑性的驱动因素对于预防疾病进展至关重要。针对驱动这种转变的基因和表观遗传改变将指导临床管理策略，并有可能预防和/或治疗致命疾病。
